Professional
Added to YB: 2024-11-04
Pitch date: 2024-10-31
ONCOZ.ST [bullish]
OncoZenge AB (publ)
-33.1%
current return
Author Info
We perform researched powered investment banking with a belief that Scandinavia will be a hotspot for the major future innovations within tech and lifescience. Visit their website.
Company Info
OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden.
Market Cap
SEK 114.8M
Pitch Price
SEK 9.82
Price Target
14.00 (+113%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-9.73
EV/Sales
26.8K
Sector
Pharmaceuticals
Category
growth
OncoZenge: Back on track
ONCOZ.ST: BupiZenge entering Phase III for oral mucositis pain relief. 61% LoA, peak sales $301M. EU partner Pharmanovia deal up to €7M milestones. New patent extends protection to 2045. $14 base case implies >50% upside from current $9. Phase III results, US deal key catalysts.
Read full article (39 min)